Latest News
Genprex secures exclusive license for Reqorsa Gene Therapy in lung cancer treatment
20 November 2024 - Clinical-stage gene therapy company Genprex, Inc. (NASDAQ:GNPX) announced on Wednesday that it has secured an exclusive worldwide license from the University of Michigan for its lead drug candidate, Reqorsa Gene Therapy (quaratusug...
Puma Biotechnology launches ALISCA-Breast1 Phase II trial for alisertib
20 November 2024 - Biopharmaceutical company Puma Biotechnology Inc (NASDAQ: PBYI) announced on Wednesday that it has commenced the ALISCA-Breast1 Phase II trial to evaluate alisertib in combination with endocrine therapy for hormone receptor-positiv...
Medtronic receives FDA clearance for InPen app
20 November 2024 - Healthcare technology company Medtronic plc (NYSE:MDT) announced on Wednesday that it has received US Food and Drug Administration (FDA) clearance for its new InPen app, which features missed meal dose detection.This clearance pave...
Poolbeg Pharma granted US Ppatent for POLB 001, expanding IP portfolio
20 November 2024 - Biopharmaceutical company Poolbeg Pharma plc (AIM: POLB) announced on Wednesday that it has secured a US patent for its Immunomodulator I application, bolstering its intellectual property portfolio.The granted claims cover POLB 001...
argenx advances efgartigimod SC for idiopathic inflammatory myopathies
20 November 2024 - Immunology company argenx SE (Euronext Brussels:ARGX) (Nasdaq:ARGX) confirmed on Wednesday that it will continue developing efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) for idiopathic inflammatory myopa...